Skip to main content
. 2018 Aug 27;7(11):e1507668. doi: 10.1080/2162402X.2018.1507668

Figure 6.

Figure 6.

Dex-treatment, but not tumor grade, influences circulating monocyte phenotype. Fresh, RBC-lysed blood from healthy donors (HD), and Dex-treated and naïve grade II-III glioma, and GBM patients was immunostained for myeloid markers (A) HLA-DR, (B) CD163, (C) CD33, and (D) PD-L1 and analyzed by flow cytometry. All frequencies are represented as the percent of CD45+, CD14+ cells. Line and error bars indicate mean and SEM.